OncLive SOSS

Year in Review: Updates in Treating Myelofibrosis - Episode 9

The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

April 3, 2024

Andrew Kuykendall, MD, Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, discusses the efficacy and adverse effects of fedratinib, highlighting its potential in the second-line setting for patients resistant to ruxolitinib, with updates from FREEDOM-2 emphasizing manageable gastrointestinal tolerability concerns.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: How JAK Inhibitors Have Shaped the Landscape of MF

EP. 2: Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

EP. 3: Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP. 4: Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP. 5: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP. 6: Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP. 7: Future Directions in Combination Therapies for Myelofibrosis

EP. 8: Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP. 9: The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP. 10: Selection and Sequencing of JAK Inhibitors for Patients With MF

EP. 11: Individualizing Therapy Goals for Patients With Myelofibrosis

EP. 12: Emerging Treatments for Myelofibrosis

x